Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
Clin Infect Dis. 2011 Jan 1;52(1):99-114. doi: 10.1093/cid/ciq067.
There is significant diversity in methicillin-resistant Staphylococcus aureus (MRSA) clones arising in the community worldwide, with considerable geographical differences in typical antimicrobial resistance profiles. Many community clones of MRSA have a non-multidrug resistant antimicrobial profile, providing increased options for empirical and directed therapy of infections caused by these strains. However, the recent description of increasing non-β lactam resistance in community clones of MRSA, especially USA300, provides a timely warning for clinicians making decisions about therapy for patients potentially infected with these strains. Continued monitoring of global epidemiology and emerging drug resistance data is critical for the effective management of these infections.
耐甲氧西林金黄色葡萄球菌(MRSA)在全球社区中出现的克隆存在显著的多样性,其典型的抗菌药物耐药谱存在很大的地理差异。许多社区型 MRSA 克隆具有非多药耐药的抗菌药物耐药谱,为这些菌株引起的感染的经验性和靶向治疗提供了更多选择。然而,最近描述的社区型 MRSA 克隆(尤其是 USA300)中非β-内酰胺类耐药性的增加,为临床医生对可能感染这些菌株的患者进行治疗决策提供了及时的警示。持续监测全球流行病学和新出现的耐药数据对于这些感染的有效管理至关重要。